Pfizer stock holds at $24.84 as company shares rare cancer journey amid continued sideways trade

Traders Union
All News
Companies
Pfizer down 0.34% today at $24.84

Highlights

Pfizer continues to face medium- and long-term downward pressure, trading below key moving averages despite short-term stabilization.
Momentum indicators are mixed, with MACD and Stoch RSI suggesting bearish exhaustion while intraday buyer strength persists.
The expected weekly range is $24.25 to $25.30, with less than 20% probability of a price increase and key resistance at $25.20.

Downside bias as price stalls below key moving averages

Pfizer ($24.84) is trading just above its MA-20 ($24.35), but below both the MA-50 ($25.20) and MA-200 ($25.87), signaling short-term stability but ongoing medium- and long-term downward pressure. The Ichimoku Kijun sits at $25.02, directly above the current price and acting as immediate resistance. Near-term support is at the MA-20 ($24.35), with key support at the MA-100 ($26.14), while immediate resistance is set by the Kijun ($25.02) and key resistance at the MA-50 ($25.20).

Divergent momentum signals amid weak trend and price softness

Momentum readings are mixed: MACD on D1 gives a strong sell signal, though ADX is neutral, highlighting a lack of trend strength. RSI (51.82) and CCI (94.31) both tilt modestly bullish, while Stoch RSI indicates overbought conditions, pointing to possible exhaustion. BBP on D1 offers a strong buy reading, indicating buyers still dominate intraday action, but the Awesome Oscillator is neutral and does not confirm the directional bias. Pfizer has slipped $0.22 (0.88%) since last week’s close at $25.06, with the price holding in the lower part of the weekly range. Weekly volatility stands at 3.25%. The tone is one of a steady decline from recent highs.

Further downside risk as bullish break faces high hurdle

For the coming week, the expected price range is $24.25 to $25.30, remaining well above the 52-week low of $23.11 and about $3 below the 52-week high of $28.74. The probability of a price increase is very low (less than 20%), signaling a higher likelihood of further downside. In the base scenario, Pfizer trades sideways within this corridor as buyer and seller momentum offset each other. A bullish break would require a sustained move above $25.20, targeting higher resistance levels, while a bearish scenario sees a fall below $24.35, opening the way to retest support towards the year’s low.

Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Previously it was reported that Pfizer remained under sustained bearish pressure, with momentum indicators suggesting limited prospects for an imminent rebound. In light of evolving market dynamics, investors should closely monitor any shifts in sentiment or emerging catalysts that could alter the current trend.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.